The deal would give the French company a pharmaceutical monopoly over Pompe Disease therapy.
The Federal Trade Commission (FTC) has taken action to prevent Sanofi from acquiring an exclusive license to a therapy that is in development for the treatment of Pompe disease. The FTC filed suit in federal court alleging that the deal would eliminate competition for the French multinational pharmaceutical and healthcare company, headquartered in Paris.
“Sanofi’s acquisition of Maze’s Pompe disease drug threatens to deprive patients of a new, innovative treatment and maintain a status quo of exorbitant pricing for essential life-saving medicines,” said FTC’s Bureau of Competition Acting Deputy Director Nate Soderstrom. “The FTC is challenging Sanofi’s deal with Maze because it’s critical that patients and doctors have access to innovative, affordable treatment options.”
As the Lord Leads, Pray with Us…
- For Chair Lina Khan as she presides over the FTC.
- For wisdom for FTC commissioners as they consider monopolies, mergers, and acquisitions.
- For those suffering from Pompe disease and the potential relief the new medication may provide.
Sources: Federal Trade Commission
